Skip to content

The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ

The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02195583
Enrollment
62
Registered
2014-07-21
Start date
2014-06-30
Completion date
2014-08-31
Last updated
2015-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Hygiene

Brief summary

This study will evaluate the effect of experimental sodium fluoride-silica dentifrice formulations, with and without zinc, on remineralization of enamel in situ. Following the remineralization phase, the acid resistance of the new mineral formed will be assessed. Fluoride uptake during the remineralization phase will also be measured.

Interventions

DRUGSodium fluoride (1426 ppm)

Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base

DRUGSodium fluoride (1150 ppm)

Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base

DRUGSodium fluoride (250 ppm)

Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base

DRUGSodium fluoride (1426 ppm) + zinc base A

Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base

DRUGSodium fluoride (1426 ppm) + zinc base B

Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base

DRUGFluoride (0 ppm)

Non-zinc, 0ppm fluoride in a silica gel base

Sponsors

GlaxoSmithKline
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Good general health with no clinically significant and relevant abnormalities of medical history or oral examination * Participants with maxillary dental arch suitable for the retention of the palatal appliance

Exclusion criteria

* Participants taking fluoride supplement * Pregnant or breast-feeding women

Design outcomes

Primary

MeasureTime frameDescription
Percentage Surface Microhardness Recovery (% SMHR)Baseline to 4 hoursChanges in the mineral content of the four centrally-located enamel specimens were evaluated using the Surface Microhardness (SMH) Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was determined prior to the in vitro acid challenge. SMH was determined again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The extent of remineralization was calculated as the % recovery in SMH using the equation: % SMHR= \[(D1-R)/(D1-B)\]\*100 Where B = indentation length (μm) of sound enamel at baseline; D1 = indentation length (μm) after first acid challenge; R = indentation length (μm) after in situ remineralization.

Secondary

MeasureTime frameDescription
Enamel Fluoride UptakeBaseline to 4 hoursThe microdrill enamel biopsy technique was used to analyze the fluoride uptake by enamel. Each enamel specimen was mounted on the long axis of a drill attached to a microdrill and drilled to a depth of approximately 100 micrometer (μm) through the entire lesion (four cores per specimen). The enamel powder pooled from four drilling sample was then immediately analyzed for fluoride content using fluoride specific electrode and pH/ion meter. The amount of fluoride-uptake by enamel was calculated based on the amount of fluoride divided by the area of the enamel cores and expressed as microgram per square centimeter (μg/cm\^2).
Percentage Net Acid Resistance (% NAR)Baseline to 4 hoursChanges in the mineral content of the four centrally-located enamel specimens were evaluated using the SMH Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was measured prior to the in vitro acid challenge. SMH was measured again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The % NAR was calculated using the equation: % NAR= \[(D1-D2)/(D1-B)\]\*100 where B= Indentation length (μm) of sound enamel at baseline; D1= Indentation length (μm) after first acid challenge and D2= Indentation length (μm) after second acid challenge.
Percentage Comparative Acid Resistance (% CAR)Baseline to 4 hoursChanges in the mineral content of the four centrally-located enamel specimens were evaluated using the SMH Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was measured prior to the in vitro acid challenge. SMH was measured again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The % CAR was calculated using the equation: % CAR= \[(D2-R)/(D1-B)\]\*100 where B= Indentation length (μm) of sound enamel at baseline; R= Indentation length (μm) of enamel after in situ remineralization; D1= Indentation length (μm) after first acid challenge; D2= Indentation length (μm) after second acid challenge.

Countries

United States

Participant flow

Recruitment details

Participants were recruited at one clinical study site in the USA.

Pre-assignment details

A total of 64 participants were screened and 62 were randomized.

Participants by arm

ArmCount
All Randomized Participants
All randomized participants were evaluated for baseline characteristics
62
Total62

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event2
Overall StudyLost to Follow-up1
Overall StudyOther Reason2
Overall StudyWithdrawal by Subject4

Baseline characteristics

CharacteristicAll Randomized Participants
Age, Continuous40.7 Years
STANDARD_DEVIATION 12.03
Sex: Female, Male
Female
39 Participants
Sex: Female, Male
Male
23 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —— / —— / —— / —
other
Total, other adverse events
3 / 591 / 575 / 551 / 584 / 605 / 59
serious
Total, serious adverse events
0 / 590 / 570 / 550 / 581 / 600 / 59

Outcome results

Primary

Percentage Surface Microhardness Recovery (% SMHR)

Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the Surface Microhardness (SMH) Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was determined prior to the in vitro acid challenge. SMH was determined again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The extent of remineralization was calculated as the % recovery in SMH using the equation: % SMHR= \[(D1-R)/(D1-B)\]\*100 Where B = indentation length (μm) of sound enamel at baseline; D1 = indentation length (μm) after first acid challenge; R = indentation length (μm) after in situ remineralization.

Time frame: Baseline to 4 hours

Population: The primary population for the efficacy analysis was the Per Protocol (PP) population, including participants with a protocol violation affecting some (but not all) of the efficacy assessments. However, data from assessments when a violation occurred were excluded.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Sodium Fluoride (1426 Ppm)Percentage Surface Microhardness Recovery (% SMHR)32.49 Percentage of SMHRStandard Error 1.167
Sodium Fluoride (1150 Ppm)Percentage Surface Microhardness Recovery (% SMHR)31.81 Percentage of SMHRStandard Error 1.182
Sodium Fluoride (250 Ppm)Percentage Surface Microhardness Recovery (% SMHR)27.56 Percentage of SMHRStandard Error 1.199
Sodium Fluoride (1426 Ppm) + Zinc Base APercentage Surface Microhardness Recovery (% SMHR)22.62 Percentage of SMHRStandard Error 1.175
Sodium Fluoride (1426 Ppm) + Zinc Base BPercentage Surface Microhardness Recovery (% SMHR)23.22 Percentage of SMHRStandard Error 1.159
Sodium Fluoride (0 Ppm)Percentage Surface Microhardness Recovery (% SMHR)24.78 Percentage of SMHRStandard Error 1.167
Comparison: Linear contrasts were fitted in order to establish whether there was a dose-response relationship. Linear contrasts were for experimental dentifrice: non-zinc treatments.p-value: <0.0001ANOVA
Comparison: Quadratic contrasts were fitted in order to establish whether there was a dose-response relationship. Quadratic contrasts are for experimental dentifrice: non-zinc treatments.p-value: 0.2274ANOVA
p-value: 0.59595% CI: [-1.84, 3.2]ANOVA
p-value: 0.000295% CI: [2.38, 7.48]ANOVA
p-value: 0.001395% CI: [1.68, 6.82]ANOVA
p-value: <0.000195% CI: [5.2, 10.21]ANOVA
p-value: <0.000195% CI: [4.51, 9.55]ANOVA
p-value: 0.032595% CI: [0.23, 5.32]ANOVA
p-value: 0.09295% CI: [-4.67, 0.35]ANOVA
p-value: 0.218595% CI: [-4.04, 0.93]ANOVA
p-value: <0.000195% CI: [7.36, 12.37]ANOVA
p-value: <0.000195% CI: [6.77, 11.75]ANOVA
Secondary

Enamel Fluoride Uptake

The microdrill enamel biopsy technique was used to analyze the fluoride uptake by enamel. Each enamel specimen was mounted on the long axis of a drill attached to a microdrill and drilled to a depth of approximately 100 micrometer (μm) through the entire lesion (four cores per specimen). The enamel powder pooled from four drilling sample was then immediately analyzed for fluoride content using fluoride specific electrode and pH/ion meter. The amount of fluoride-uptake by enamel was calculated based on the amount of fluoride divided by the area of the enamel cores and expressed as microgram per square centimeter (μg/cm\^2).

Time frame: Baseline to 4 hours

Population: The main population for the secondary efficacy analysis was the PP population, including participants with a protocol violation affecting some (but not all) of the efficacy assessments. However, data from assessments when a violation occurred were excluded.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Sodium Fluoride (1426 Ppm)Enamel Fluoride Uptake2.94 microgram per square centimeter(μg/cm^2)Standard Error 0.083
Sodium Fluoride (1150 Ppm)Enamel Fluoride Uptake2.70 microgram per square centimeter(μg/cm^2)Standard Error 0.084
Sodium Fluoride (250 Ppm)Enamel Fluoride Uptake1.85 microgram per square centimeter(μg/cm^2)Standard Error 0.085
Sodium Fluoride (1426 Ppm) + Zinc Base AEnamel Fluoride Uptake2.62 microgram per square centimeter(μg/cm^2)Standard Error 0.083
Sodium Fluoride (1426 Ppm) + Zinc Base BEnamel Fluoride Uptake2.37 microgram per square centimeter(μg/cm^2)Standard Error 0.082
Sodium Fluoride (0 Ppm)Enamel Fluoride Uptake0.98 microgram per square centimeter(μg/cm^2)Standard Error 0.083
Secondary

Percentage Comparative Acid Resistance (% CAR)

Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the SMH Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was measured prior to the in vitro acid challenge. SMH was measured again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The % CAR was calculated using the equation: % CAR= \[(D2-R)/(D1-B)\]\*100 where B= Indentation length (μm) of sound enamel at baseline; R= Indentation length (μm) of enamel after in situ remineralization; D1= Indentation length (μm) after first acid challenge; D2= Indentation length (μm) after second acid challenge.

Time frame: Baseline to 4 hours

Population: The main population for the secondary efficacy analysis was the PP population, including participants with a protocol violation affecting some (but not all) of the efficacy assessments. However, data from assessments when a violation occurred were excluded.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Sodium Fluoride (1426 Ppm)Percentage Comparative Acid Resistance (% CAR)45.00 Percentage of CARStandard Error 1.274
Sodium Fluoride (1150 Ppm)Percentage Comparative Acid Resistance (% CAR)45.23 Percentage of CARStandard Error 1.295
Sodium Fluoride (250 Ppm)Percentage Comparative Acid Resistance (% CAR)45.44 Percentage of CARStandard Error 1.319
Sodium Fluoride (1426 Ppm) + Zinc Base APercentage Comparative Acid Resistance (% CAR)40.29 Percentage of CARStandard Error 1.285
Sodium Fluoride (1426 Ppm) + Zinc Base BPercentage Comparative Acid Resistance (% CAR)42.21 Percentage of CARStandard Error 1.264
Sodium Fluoride (0 Ppm)Percentage Comparative Acid Resistance (% CAR)75.41 Percentage of CARStandard Error 1.274
Secondary

Percentage Net Acid Resistance (% NAR)

Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the SMH Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was measured prior to the in vitro acid challenge. SMH was measured again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The % NAR was calculated using the equation: % NAR= \[(D1-D2)/(D1-B)\]\*100 where B= Indentation length (μm) of sound enamel at baseline; D1= Indentation length (μm) after first acid challenge and D2= Indentation length (μm) after second acid challenge.

Time frame: Baseline to 4 hours

Population: The main population for the secondary efficacy analysis was the PP population, including participants with a protocol violation affecting some (but not all) of the efficacy assessments. However, data from assessments when a violation occurred were excluded.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Sodium Fluoride (1426 Ppm)Percentage Net Acid Resistance (% NAR)-12.54 Percentage of NARStandard Error 1.224
Sodium Fluoride (1150 Ppm)Percentage Net Acid Resistance (% NAR)-13.45 Percentage of NARStandard Error 1.244
Sodium Fluoride (250 Ppm)Percentage Net Acid Resistance (% NAR)-17.81 Percentage of NARStandard Error 1.266
Sodium Fluoride (1426 Ppm) + Zinc Base APercentage Net Acid Resistance (% NAR)-17.60 Percentage of NARStandard Error 1.234
Sodium Fluoride (1426 Ppm) + Zinc Base BPercentage Net Acid Resistance (% NAR)-18.98 Percentage of NARStandard Error 1.214
Sodium Fluoride (0 Ppm)Percentage Net Acid Resistance (% NAR)-50.60 Percentage of NARStandard Error 1.224

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026